Advertisement
Singapore markets open in 6 hours 35 minutes
  • Straits Times Index

    3,144.76
    -38.85 (-1.22%)
     
  • S&P 500

    5,050.96
    -10.86 (-0.21%)
     
  • Dow

    37,784.29
    +49.18 (+0.13%)
     
  • Nasdaq

    15,869.32
    -15.70 (-0.10%)
     
  • Bitcoin USD

    62,571.07
    -866.27 (-1.37%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,820.36
    -145.17 (-1.82%)
     
  • Gold

    2,406.70
    +23.70 (+0.99%)
     
  • Crude Oil

    85.36
    -0.05 (-0.06%)
     
  • 10-Yr Bond

    4.6530
    +0.0250 (+0.54%)
     
  • Nikkei

    38,471.20
    -761.60 (-1.94%)
     
  • Hang Seng

    16,248.97
    -351.49 (-2.12%)
     
  • FTSE Bursa Malaysia

    1,535.00
    -7.53 (-0.49%)
     
  • Jakarta Composite Index

    7,164.81
    -122.07 (-1.68%)
     
  • PSE Index

    6,404.97
    -157.46 (-2.40%)
     

Could This Drug News Lift AbbVie's Stock?

Could This Drug News Lift AbbVie's Stock?

Consider AbbVie's (NYSE: ABBV) crown jewel drug, Humira, which hauled in $21.2 billion in revenue in 2022. The good news is that AbbVie knew this day would come and has been preparing. SLE is an autoimmune disease that affects multiple organs of the body.